Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades

Stock Track05-06

Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.

The significant price movement appears to be driven by the publication of expert recommendations for glucocorticoid dose reduction after initiating Crenessity® (crinecerfont) for the treatment of classic congenital adrenal hyperplasia. This peer-reviewed guidance, published in the Journal of Clinical Endocrinology & Metabolism, provides clinical algorithms that frame Crenessity as enabling more physiologic steroid replacement while maintaining androgen control, which could reduce risks associated with long-term glucocorticoid exposure.

Additionally, the stock received multiple analyst upgrades and positive ratings. Several major financial institutions, including RBC, Piper Sandler, Citigroup, Oppenheimer, Morgan Stanley, and Wedbush, raised their price targets on Neurocrine Biosciences, reflecting growing analyst confidence in the company's prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139698801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139698801","market":"us","top_or_hot":-1,"title":"Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades","media":"Stock Track","content":"<p>Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.</p><p>The significant price movement appears to be driven by the publication of expert recommendations for glucocorticoid dose reduction after initiating Crenessity® (crinecerfont) for the treatment of classic congenital adrenal hyperplasia. This peer-reviewed guidance, published in the Journal of Clinical Endocrinology & Metabolism, provides clinical algorithms that frame Crenessity as enabling more physiologic steroid replacement while maintaining androgen control, which could reduce risks associated with long-term glucocorticoid exposure.</p><p>Additionally, the stock received multiple analyst upgrades and positive ratings. Several major financial institutions, including RBC, Piper Sandler, Citigroup, Oppenheimer, Morgan Stanley, and Wedbush, raised their price targets on Neurocrine Biosciences, reflecting growing analyst confidence in the company's prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.</p><p>The significant price movement appears to be driven by the publication of expert recommendations for glucocorticoid dose reduction after initiating Crenessity® (crinecerfont) for the treatment of classic congenital adrenal hyperplasia. This peer-reviewed guidance, published in the Journal of Clinical Endocrinology & Metabolism, provides clinical algorithms that frame Crenessity as enabling more physiologic steroid replacement while maintaining androgen control, which could reduce risks associated with long-term glucocorticoid exposure.</p><p>Additionally, the stock received multiple analyst upgrades and positive ratings. Several major financial institutions, including RBC, Piper Sandler, Citigroup, Oppenheimer, Morgan Stanley, and Wedbush, raised their price targets on Neurocrine Biosciences, reflecting growing analyst confidence in the company's prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"","article_id":"1139698801","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139698801","pubTimestamp":1778075761,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.The significant price movement appears to be driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"个股追踪|Neurocrine Biosciences盘前飙升5.86%，因利好Crenessity消息和分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Neurocrine Biosciences' stock surged 5.86% in pre-market trading on Wednesday, indicating strong investor interest ahead of the regular session.The significant price movement appears to be driven by the publication of expert recommendations for glucocorticoid dose reduction after initiating Crenessity® (crinecerfont) for the treatment of classic congenital adrenal hyperplasia. This peer-reviewed guidance, published in the Journal of Clinical Endocrinology & Metabolism, provides clinical algorithms that frame Crenessity as enabling more physiologic steroid replacement while maintaining androgen control, which could reduce risks associated with long-term glucocorticoid exposure.Additionally, the stock received multiple analyst upgrades and positive ratings. Several major financial institutions, including RBC, Piper Sandler, Citigroup, Oppenheimer, Morgan Stanley, and Wedbush, raised their price targets on Neurocrine Biosciences, reflecting growing analyst confidence in the company's prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139698801","isCrawlerRequest":true}